Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025British Journal of Haematology

Decoding the molecular drivers of TP53 ‐mutant acute myeloid leukaemia: Clinical implications and prognostic insights

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYu WangXZXiaohui ZhangXHXiao‐Jun Huang

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals venetoclax improves outcomes in acute myeloid leukaemia with TP53 mutations, highlighting RUNX1 involvement.

Key Points

  • Combined venetoclax and hypomethylating agent treatment increased complete remission rates to 53.8%.
  • TP53 V272 mutation correlated with a 0% relapse rate, while multivariate analysis revealed RUNX1‐RUNX1T1 fusion gene significantly impacts patient outcomes.
  • Assessment of 193 TP53‐mutant acute myeloid leukaemia patients showed better survival rates with specific mutations and treatment regimens.
  • Clinical implications stress the importance of molecular drivers in guiding therapy for acute myeloid leukaemia patients with TP53 mutations.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/6930dc78ea1aef094cca23a9https://doi.org/10.1111/bjh.70271
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation2026
  2. 2TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy2025
  3. 3<i>TP53</i> variant allele frequency as a driver of survival in <i>TP53</i> -mutated acute myeloid leukemia.2026
  4. 4Prognosis of Acute Myeloid Leukemia Based on TP53 Mutation Among Adult Patients: A Systematic Review and Meta-Analysis.2026
  5. 5Real-world outcomes of TP53-mutated acute myeloid leukemia at a single institution.2026